Mild cognitive impairment clinical trials

[1]  P. Lestage,et al.  Cognition enhancing or neuroprotective compounds for the treatment of cognitive disorders: why? when? which? , 2003, Experimental Gerontology.

[2]  E. Tangalos,et al.  CME Practice parameter: , 2022 .

[3]  J. Kornhuber,et al.  Memantine in moderate-to-severe Alzheimer's disease. , 2003, The New England journal of medicine.

[4]  John Hardy,et al.  Amyloid, the presenilins and Alzheimer's disease , 1997, Trends in Neurosciences.

[5]  J. Hardy,et al.  Amyloid deposition as the central event in the aetiology of Alzheimer's disease. , 1991, Trends in pharmacological sciences.

[6]  C. Jack,et al.  Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment , 1999, Neurology.

[7]  K. Davis,et al.  Inflammatory mechanisms in Alzheimer's disease: implications for therapy. , 1994, The American journal of psychiatry.

[8]  Ronald Carl Petersen,et al.  Mild cognitive impairment : aging to Alzheimer's disease , 2003 .

[9]  N Butters,et al.  Detection of abnormal memory decline in mild cases of Alzheimer's disease using CERAD neuropsychological measures. , 1991, Archives of neurology.

[10]  R Brookmeyer,et al.  Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. , 1998, American journal of public health.

[11]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[12]  K. Frick,et al.  Sex differences in neurochemical markers that correlate with behavior in aging mice , 2002, Neurobiology of Aging.

[13]  R. Lipton,et al.  Telephone screening for amnestic mild cognitive impairment , 2003, Neurology.

[14]  Steven A. Johnson,et al.  Randomized, double-blind, placebo-controlled international clinical trial of the Ampakine® CX516 in elderly participants with mild cognitive impairment , 2002, Journal of Molecular Neuroscience.

[15]  C. Reynolds,et al.  Wechsler memory scale-revised , 1988 .

[16]  Walter Kukull,et al.  Progression to dementia in patients with isolated memory loss , 1997, The Lancet.

[17]  D. Schenk.  Alzheimer's disease: A partner for presenilin , 2000, Nature.

[18]  R. Katzman.,et al.  The World-Wide Impact of Dementia. Projections of Prevalance and Costs , 1999 .

[19]  H. Wiśniewski,et al.  Alzheimer's disease and related disorders. , 1986, British medical bulletin.

[20]  R. Nitsch,et al.  Generation of antibodies specific for β-amyloid by vaccination of patients with Alzheimer disease , 2002, Nature Medicine.

[21]  R. Petersen,et al.  Aging, mild cognitive impairment, and Alzheimer's disease. , 2000, Neurologic clinics.

[22]  B. Reisberg,et al.  The Global Deterioration Scale for assessment of primary degenerative dementia. , 1982, The American journal of psychiatry.

[23]  R. Petersen.  Mild cognitive impairment or questionable dementia? , 2000, Archives of neurology.

[24]  B. Winblad,et al.  Clinical Efficacy of Piracetam in Cognitive Impairment: A Meta-Analysis , 2002, Dementia and Geriatric Cognitive Disorders.

[25]  K. Henke,et al.  Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. , 2003, Neuron.

[26]  C. P. Hughes,et al.  A New Clinical Scale for the Staging of Dementia , 1982, British Journal of Psychiatry.

[27]  A. Sanabria,et al.  Randomized controlled trial. , 2005, World journal of surgery.

[28]  S. Leeder,et al.  A population based study , 1993, The Medical journal of Australia.

[29]  S. Younkin,et al.  Processing of the Alzheimer's Disease ΒZA4 Amyloid Protein Precursor (APP) , 1991 .

[30]  D. Westaway,et al.  Therapeutically effective antibodies against amyloid-β peptide target amyloid-β residues 4–10 and inhibit cytotoxicity and fibrillogenesis , 2002, Nature Medicine.

[31]  P. Aisen,et al.  Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer's disease brain , 1998, Neuroscience.

[32]  P Woodbury,et al.  A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. , 1997, The New England journal of medicine.

[33]  C. Cotman,et al.  Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study. , 2000, JAMA.

[34]  D. Zaitchik,et al.  Predicting conversion to Alzheimer disease using standardized clinical information. , 2000, Archives of neurology.

[35]  K. Davis,et al.  Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. , 2003, JAMA.

[36]  L. Thal,et al.  A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study. , 2000, Neurology.

[37]  C. Jack,et al.  Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease , 1997, Neurology.

[38]  H. Amièva,et al.  Incidence and outcome of mild cognitive impairment in a population-based prospective cohort , 2002, Neurology.

[39]  J. Morris,et al.  Current concepts in mild cognitive impairment. , 2001, Archives of neurology.

[40]  D. A. Bennett,et al.  Natural history of mild cognitive impairment in older persons , 2002, Neurology.

[41]  R. Barbour,et al.  Purification and cloning of amyloid precursor protein β-secretase from human brain , 1999, Nature.

[42]  Y. Christen,et al.  Epidemiology of Alzheimer’s Disease: From Gene to Prevention , 2011, Research and Perspectives in Alzheimer’s Disease.

[43]  O. Lopez.  [Classification of mild cognitive impairment in a population study]. , 2003, Revista de neurologia.

[44]  E. Cochran,et al.  Loss of nucleus basalis neurons containing trkA immunoreactivity in individuals with mild cognitive impairment and early Alzheimer's disease , 2000, The Journal of comparative neurology.

[45]  Janice E Graham,et al.  Prevalence and severity of cognitive impairment with and without dementia in an elderly population , 1997, The Lancet.

[46]  E. Tangalos,et al.  The short test of mental status. Correlations with standardized psychometric testing. , 1991, Archives of neurology.

[47]  B. Winblad,et al.  Alzheimer's disease : advances in etiology, pathogenesis, and therapeutics , 2001 .

[48]  S. Ferris,et al.  Age‐associated memory impairment: Proposed diagnostic criteria and measures of clinical change — report of a national institute of mental health work group , 1986 .

[49]  Alfredo G. Tomasselli,et al.  Membrane-anchored aspartyl protease with Alzheimer's disease β-secretase activity , 1999, Nature.

[50]  J. Breitner.  Inflammatory processes and antiinflammatory drugs in Alzheimer's disease: A current appraisal , 1996, Neurobiology of Aging.

[51]  J. Treanor,et al.  Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. , 1999, Science.

[52]  J. Cummings,et al.  Alzheimer's Disease and Related Disorders Annual - 2001 , 2001 .

[53]  E. Tangalos,et al.  Mild Cognitive Impairment Clinical Characterization and Outcome , 1999 .

[54]  Yaakov Stern,et al.  Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease , 1996, The Lancet.

[55]  M N Rossor,et al.  Presymptomatic cognitive deficits in individuals at risk of familial Alzheimer's disease. A longitudinal prospective study. , 1998, Brain : a journal of neurology.

[56]  E G Tangalos,et al.  Postmenopausal estrogen replacement therapy and risk of AD , 1999, Neurology.

[57]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.

[58]  Jeffrey L. Cummings,et al.  Practice parameter: Diagnosis of dementia (an evidence-based review) Report of the Quality Standards Subcommittee of the American Academy of Neurology , 2001 .

[59]  Rong Wang,et al.  A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity , 2001, Nature.

[60]  R. S. Doody, MD, PhD,et al.  Practice parameter: Management of dementia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology , 2001 .

[61]  L. Launer.  Nonsteroidal anti-inflammatory drugs and Alzheimer disease: what's next? , 2003, JAMA.

[62]  R. Lévy,et al.  Aging-Associated Cognitive Decline , 1994, International Psychogeriatrics.

[63]  V. A. Kral,et al.  Senescent forgetfulness: benign and malignant. , 1962, Canadian Medical Association journal.

[64]  K. Davis,et al.  A new rating scale for Alzheimer's disease. , 1984, The American journal of psychiatry.

[65]  D. Selkoe,et al.  Nasal administration of amyloid‐β peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease , 2000, Annals of neurology.

[66]  Leslie Carol Botha.  Estrogen Plus Progestin and the Incidence of Dementia and Mild Cognitive Impairment in Postmenopausal Women , 2003 .

[67]  Karen Ritchie,et al.  Classification criteria for mild cognitive impairment: A population-based validation study , 2001 .

[68]  Richard Granger,et al.  Evidence That a Positive Modulator of AMPA-Type Glutamate Receptors Improves Delayed Recall in Aged Humans , 1997, Experimental Neurology.

[69]  David G. Tew,et al.  Identification of a Novel Aspartic Protease (Asp 2) as β-Secretase , 1999, Molecular and Cellular Neuroscience.

[70]  K. Davis,et al.  Cholinergic markers in elderly patients with early signs of Alzheimer disease. , 1999, JAMA.

[71]  J. Dickens,et al.  Prevalence of cognitive impairment: Data from the Indianapolis Study of Health and Aging , 2001 .

[72]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.

[73]  K. Henke,et al.  Antibodies against β-Amyloid Slow Cognitive Decline in Alzheimer's Disease , 2003, Neuron.

[74]  J. Hardy,et al.  The presenilins and Alzheimer's disease. , 1997, Human molecular genetics.